Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Update

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the recipient of a significant growth in short interest during the month of January. As of January 15th, there was short interest totaling 274,164 shares, a growth of 70.8% from the December 31st total of 160,518 shares. Currently, 19.6% of the company’s stock are sold short. Based on an average trading volume of 1,037,269 shares, the days-to-cover ratio is presently 0.3 days. Based on an average trading volume of 1,037,269 shares, the days-to-cover ratio is presently 0.3 days. Currently, 19.6% of the company’s stock are sold short.

Shuttle Pharmaceuticals Trading Down 7.8%

NASDAQ SHPH opened at $2.02 on Friday. Shuttle Pharmaceuticals has a 1 year low of $1.26 and a 1 year high of $19.95. The company has a fifty day simple moving average of $1.77 and a 200 day simple moving average of $2.88. The company has a market cap of $3.23 million, a P/E ratio of -0.17 and a beta of -1.00.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last announced its earnings results on Thursday, November 13th. The company reported ($1.05) EPS for the quarter.

Institutional Trading of Shuttle Pharmaceuticals

A hedge fund recently bought a new stake in Shuttle Pharmaceuticals stock. Connective Capital Management LLC bought a new stake in Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 100,535 shares of the company’s stock, valued at approximately $357,000. Connective Capital Management LLC owned about 9.40% of Shuttle Pharmaceuticals as of its most recent SEC filing. Institutional investors own 4.58% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on SHPH shares. Weiss Ratings restated a “sell (e+)” rating on shares of Shuttle Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen raised shares of Shuttle Pharmaceuticals to a “sell” rating in a research report on Saturday, November 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .